Chong Kun Dang Pharmaceutical Corp. Expands Diabetes Business Into Continuous Glucose Monitors, Teams Up With HLB LifeCare

[Financial News] Chong Kun Dang Pharmaceutical Corp. is expanding its business beyond diabetes drugs into the distribution of continuous glucose monitoring (CGM) devices. The company aims to broaden its diabetes-related business, previously centered on pharmaceuticals, to include blood glucose monitoring devices and build a business model that spans patient treatment and day-to-day blood glucose management.
HLB LifeCare announced on the 13th that it had signed a domestic sales agreement with Chong Kun Dang Pharmaceutical Corp. for its continuous glucose monitor, Picoling. HLB LifeCare will supply the product, while Chong Kun Dang Pharmaceutical Corp. will handle distribution, sales and marketing through domestic hospitals and clinics, Chong Kun Dang Mall and other channels.
The agreement combines HLB LifeCare's product supply capabilities with Chong Kun Dang Pharmaceutical Corp.'s diabetes drug portfolio and sales network. By linking the product to its existing diabetes drug business, Chong Kun Dang Pharmaceutical Corp. can expand its reach into the blood glucose management device market, while HLB LifeCare can increase product sales by leveraging Chong Kun Dang Pharmaceutical Corp.'s distribution network.
Picoling uses a sensor attached to the skin to continuously measure changes in blood glucose for up to 15 days without blood sampling. It can be used by children aged 2 and older as well as adults, and has an IP68-rated dust- and water-resistance performance.
Measurement data can be viewed in the dedicated My Picoling app. Patients, caregivers and medical professionals can share the data to monitor trends in blood glucose changes. Healthcare institutions are provided with a web dashboard for viewing each patient's measurements and AI-powered analysis reports.

[email protected] Jung Sang-hee Reporter